Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation.
about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseNMR Meets Tau: Insights into Its Function and PathologyTau Biology and Tau-Directed Therapies for Alzheimer's DiseaseIntrinsic Tau Acetylation Is Coupled to Auto-Proteolytic Tau FragmentationStructural determinants of Tau aggregation inhibitor potencyPreventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicityPAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.Role of the Keap1/Nrf2 pathway in neurodegenerative diseases.Structure and mechanism of action of tau aggregation inhibitors.Inhibition of tau aggregation by a rosamine derivative that blocks tau intermolecular disulfide cross-linking.Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies.Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment.Inhibition of Both Hsp70 Activity and Tau Aggregation in Vitro Best Predicts Tau Lowering Activity of Small Molecules.A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.Protein phosphorylation in neurodegeneration: friend or foe?Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.Methylene Blue Inhibits Caspases by Oxidation of the Catalytic Cysteine.Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease.Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.Emerging amyloid and tau targeting treatments for Alzheimer's disease.New routes in frontotemporal dementia drug discovery.Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497.Emerging Diagnostic and Therapeutic Strategies for Tauopathies.From Mitochondrial Function to Neuroprotection-an Emerging Role for Methylene Blue.Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy?Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.TPPU protects tau from H2O2-induced hyperphosphorylation in HEK293/tau cells by regulating PI3K/AKT/GSK-3β pathway.Chemical motifs that redox cycle and their associated toxicity
P2860
Q26739412-E0AA986D-73F7-4BCD-89B1-D4BA998016CEQ26747418-F4F0720D-C9AB-4092-B5E8-50E87F8F446FQ28071398-624994B3-F0E6-4E29-841D-539AEFC731C4Q28552366-EE1BC883-119F-4522-BA70-9D0634D23526Q30353954-FF5671D9-F1D2-4505-AE7D-CD4D7F091AA4Q30649677-B4083CE7-4F93-4CC8-A18D-92E843E62492Q33784466-2024AABB-5067-4748-A209-7F28E681F1D0Q34460371-2D6D8E7E-BEB5-4BDB-BE23-2C2F5D1F408AQ34464138-2B510865-A3A6-459C-9492-0F1868C6A726Q34902096-A2D9369C-AC5E-4D03-A687-6EC6B222BF77Q35185595-FFF7386E-5351-45DF-A6A8-7540D4D84944Q35669674-0F896A48-645B-4087-A087-6674347EE79DQ37314665-575224B7-D556-4E22-B560-3B48A64BA7F3Q37417421-8A98C9B9-7190-4694-A478-DB89DFFF48C5Q37695237-25C5F4C1-E7BB-4AC4-8F08-79B372C10EC2Q38214594-86F3B15A-5D2D-4E2B-ACC3-F33C05108B6DQ38715233-19A13796-0F07-4DF6-9296-BAC5254DBB09Q38797428-93567C74-BD39-4678-A9CF-5BCE51746821Q38833034-F0CACD29-9D45-4806-B93D-87976CB27E23Q38850493-C5C43DC3-6D61-4B75-A3C9-86D1D5D3E918Q38983187-4C475F28-084D-4DF0-9A6D-F7F2FE2CE6D0Q39035486-151D7AAF-76AD-41CF-88EA-A81EEB5F14A4Q39296311-E7E4124F-7E95-425F-AE30-8878A6ADC078Q39344391-14450C1E-000D-4465-95A3-7D6D70988F85Q39692816-07DA0630-B968-44B0-8F9D-DE0512C0C9F5Q45870549-F672F436-1CFB-439E-A50F-7F481EDAE820Q48004149-71F9A998-BCF0-410E-A806-79A04AB3CDDEQ48239696-740EC618-B868-4ECD-B990-4225E441FA2AQ50632272-6AAC404A-5B35-41F5-9514-E58AFDDC0B52Q51282001-C5E0A988-CC89-4E3F-87D4-ABC1929ABF55Q58293268-264094FD-3264-4D34-A741-698387EC50D2
P2860
Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Aminothienopyridazines and met ...... zation via cysteine oxidation.
@ast
Aminothienopyridazines and met ...... zation via cysteine oxidation.
@en
type
label
Aminothienopyridazines and met ...... zation via cysteine oxidation.
@ast
Aminothienopyridazines and met ...... zation via cysteine oxidation.
@en
prefLabel
Aminothienopyridazines and met ...... zation via cysteine oxidation.
@ast
Aminothienopyridazines and met ...... zation via cysteine oxidation.
@en
P2093
P2860
P356
P1476
Aminothienopyridazines and met ...... zation via cysteine oxidation.
@en
P2093
Alex Crowe
Amos B Smith
Carlo Ballatore
Kurt R Brunden
Michael J James
Virginia M-Y Lee
P2860
P304
11024-11037
P356
10.1074/JBC.M112.436006
P407
P577
2013-02-26T00:00:00Z